A New Standard in First-Line Therapy for HER2-Positive Breast Cancer?

(MedPage Today) -- In the DESTINY-Breast09 trial, presented at this year's American Society of Clinical Oncology (ASCO) annual meeting, first-line trastuzumab deruxtecan (T-DXd; Enhertu) combined with pertuzumab (Perjeta) improved progression-free...